Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.14
- Piotroski Score 5.00
- Grade Overweight
- Symbol (CERS)
- Company Cerus Corporation
- Price $1.66
- Changes Percentage (-3.47%)
- Change -$0.06
- Day Low $1.65
- Day High $1.75
- Year High $2.59
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $5.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.17
- Trailing P/E Ratio -10.47
- Forward P/E Ratio -10.47
- P/E Growth -10.47
- Net Income $-37,489,000
Income Statement
Quarterly
Annual
Latest News of CERS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Late Quincy Jones, Bond film producers bestowed with honorary Oscars
By Mary MillikenLOS ANGELES (Reuters) - Just weeks after his death at the age of 91, renowned music producer and composer Quincy Jones was bestowed with an honorary Oscar by Hollywood's film acade...
By Reuters | 22 hours ago -
Trump transition team compiling list of current and former U.S. military officers for possible courts-martial
The Trump transition team is considering investigating and potentially court-martialing military officers involved in the Afghanistan withdrawal. The review aims to assess decision-making processes an...
By NBC News | 2 days ago -
Prosecutors say officers involved in fatal shooting of Salina man won't be charged
Authorities in Kansas announced that police officers and troopers who fatally shot a man in Salina were justified and won't face charges. The man, Jesse Wray, pointed a gun at officers and posed a thr...
By AP NEWS | 2 days ago
